Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.
| Autor: | Ather, Ferdows1, Hamidi, Habib1 hhamidi@mednet.ucla.edu, Fejzo, Marlena S.1, Letrent, Stephen2, Finn, Richard S.1, Kabbinavar, Fairooz1, Head, Christian1, Wong, Steven G.1 |
|---|---|
| Zdroj: | PLoS ONE. Feb2013, Vol. 8 Issue 2, p1-15. 15p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|